asp8062
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 8, 2017 (NCT03092726)
Timeline
Indications
Mechanism of action
- GABA-B receptor 1INHIBITOR
GABBR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- asp8062
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05096117 | Phase 2 | Dec 1, 2021 | Astellas, National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT05062577 | Phase 2 | Oct 8, 2021 | Astellas |
| NCT04447287 | Phase 1 | Jun 29, 2020 | Astellas |
| NCT04003402 | Phase 1 | Jul 31, 2019 | Astellas |
| NCT03183739 | Phase 1 | Jun 1, 2017 | Astellas |
| NCT03092726 | Phase 2 | May 8, 2017 | Astellas |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 6 | 5 | 2 | 2017 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1